Granules India’s Bonthapally Facility Completed US FDA Inspection
Granules India Ltd’s Bonthapally facility located at Hyderabad, Telangana, India has completed the US FDA inspection from 22nd July 2019 to 26th July 2019 with...
Continue ReadingGranules India Ltd’s Bonthapally facility located at Hyderabad, Telangana, India has completed the US FDA inspection from 22nd July 2019 to 26th July 2019 with...
Continue ReadingCould a manufacturing mix-up be as detrimental as the fact that a drug simply doesn’t work? Nektar learned the answer the hard way with its...
Continue ReadingDrug firm Lupin said that it has received an Establishment Inspection Report (EIR) from the US health regulator for its Aurangabad facility in Maharashtra. The...
Continue ReadingMylan N. V. and Pfizer announced a definitive agreement to combine Mylan with Upjohn, Pfizer’s off-patent branded and generic established medicines business, creating a new...
Continue ReadingNovartis Chief Executive Vas Narasimhan pledged in an interview not to sell the Swiss drugmaker’s generics unit Sandoz amid a revamp that has prompted speculation...
Continue ReadingNovadoz Pharmaceuticals, the U.S based sales & marketing affiliate for MSN Labs, based in Hyderabad India, has received FDA approval for their generic version of...
Continue ReadingKatherine Eban’s new book, “Bottle of Lies,” has focused a very intense spotlight on the mostly ignored transgressions of the Indian generic pharmaceutical industry in...
Continue ReadingSkilled manpower and improved quality of medicines and more focus on foreign markets have helped Bangladesh to expand its pharma market to 144 countries. Bangladesh’s...
Continue ReadingChecking your phone at the doctor’s office? Don’t be surprised if you get an ad for a drug you can talk to your doctor about....
Continue Reading